<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03623282</url>
  </required_header>
  <id_info>
    <org_study_id>AG-SYN-01</org_study_id>
    <nct_id>NCT03623282</nct_id>
  </id_info>
  <brief_title>Study Regarding the Clinical Efficacy of Synatura® in Patients With Chronic Bronchitis Type COPD</brief_title>
  <official_title>Study Regarding the Clinical Efficacy of Synatura® in Patients With Chronic Bronchitis Type COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahn-Gook Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ahn-Gook Pharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to examine the clinical efficacy of synatura in patients with chronic
      bronchitis type COPD in Korea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Synatura® is a drug commonly used to suppress cough and sputum in patients with acute upper
      respiratory tract infection and chronic inflammatory bronchitis. According to the Phase III
      studies conducted in Korea, the safety and efficacy of Synatura® on antitussive and
      expectorant effects were confirmed in patients with acute upper respiratory infection and
      chronic inflammatory bronchitis. However, no studies have been conducted for the effects of
      Synatura® in patients with COPD. COPD is divided into emphysema type and chronic bronchitis
      type, while typical clinical symptoms of chronic bronchitis are cough and sputum. Therefore,
      Synatura®, which is effective for chronic bronchitis, is expected to be effective in patients
      with chronic bronchitis accompanied by COPD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Actual">May 2, 2018</completion_date>
  <primary_completion_date type="Actual">May 2, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Experimental(Single arm):
The enrolled patients will be prescribed Synatura® following measurement of pre-dose pulmonary functions, quality of life and systemic inflammatory state. Pulmonary functions, quality of life and systemic inflammatory state will be repeatedly measured after taking Synatura® for 3 months, and the changes from pre-dose measurements will be observed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COPD assessment test (CAT)</measure>
    <time_frame>Baseline, At 12weeks</time_frame>
    <description>Change from Baseline in baseline to 12 weeks for COPD assessment test (CAT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of pulmonary function in bronchitis type COPD patients</measure>
    <time_frame>Baseline, At 12weeks</time_frame>
    <description>Pulmonary function test will be performed before and 3 months after taking Synatura.
Assessment Tools: FVC (L), FVC (%), FEV1 (L), FEV1 (%), FEV1/FVC (%), TLC (%), RV (%), RV/TLC (%), DLCO (%), DLCO/VA (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of inflammation throughout the body in bronchitis type COPD patients</measure>
    <time_frame>Baseline, At 12weeks</time_frame>
    <description>Blood samples will be taken before and 3 months after taking Synatura, then stored and measured by ELISA in the laboratory.
Assessment Tools: CRP, Fibrinogen, IL-6, TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of Bronchitis Severity Score (BSS)</measure>
    <time_frame>Baseline, At 12weeks</time_frame>
    <description>Bronchitis Severity Score (BSS) will be performed before and 3 months after taking Synatura
The BSS measured cough, sputum, rales/ rhonchi, chest pain during coughing, and dyspnoea. Each of these features of acute bronchitis was scored by a welltrained doctor using a 5point Likert rating scale ranging from 0 to 4 (0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe)
The overall BSS will be graded as mild (0-7), moderate (8-14), and severe (15,20).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Bronchitis, COPD</condition>
  <arm_group>
    <arm_group_label>Synatura® 15 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Synatura syrup single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synatura® 15 mL</intervention_name>
    <description>All subjects will receive Synatura® 15 mL every day three times for 3 months.</description>
    <arm_group_label>Synatura® 15 mL</arm_group_label>
    <other_name>AG NPP709</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Post bronchodilator FEV1/FVC &lt; 0.7

          2. Smoking history of ≥10 packs per year

          3. 40 to &lt;75 years of age

          4. Patients with symptoms of chronic bronchitis (in case they have symptoms of cough or
             sputum over 3 months)

        Exclusion Criteria:

          1. Patients with acute exacerbation

          2. Patients with pneumonia

          3. Patients with active tuberculosis

          4. Pregnant women

          5. Breast-feeding women

          6. Patients with fructose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chinkook Rhee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul St. Mary's hospital</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Synatura</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Ahn Gook Pharmaceuticals</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 25, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03623282/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

